<![CDATA[Saxenda continues to dominate the market and now commands 50.4%, up 0.6 pp w/w, based on value market share, or 14.3%, up 0.8 pp w/w, based on volume market share. Among the basal insulins, Tresiba gr]]>

<![CDATA[Saxenda continues to dominate the market and now commands 50.4%, up 0.6 pp w/w, based on value market share, or 14.3%, up 0.8 pp w/w, based on volume market share. Among the basal insulins, Tresiba gr]]>Saxenda continues to dominate the market and now commands 50.4%, up 0.6 pp w/w, based on value market share, or 14.3%, up 0.8 pp w/w, based on volume market share. Among the basal insulins, Tresiba grew 4.5% w/w to reach 16,941 weekly prescriptions, while Levemir, up 0.8%, lagged behind the overall US basal insulin market, growing 1.5% w/w. Novo's combined TRx market share was down 0.1 pp w/w to 25.8%, with Tresiba
capturing 3.4% (NRx4.4%), up 0.1 pp w/w.

]]>https://dev.proinvestor.com/forum/topic/398421/saxenda-continues-to-dominate-the-market-and-now-commands-504-up-06-pp-ww-based-on-value-market-share-or-143-up-08-pp-ww-based-on-volume-market-share-among-the-basal-insulins-tresiba-grRSS for NodeSat, 06 Jun 2026 16:11:13 GMTFri, 25 Aug 2023 03:38:22 GMT60